

Title (en)
NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C

Title (de)
NUKLEOTIDDERIVATE, DIE HCV-INHIBITOREN SIND, ZUR VERWENDUNG IN DER BEHANDLUNG VON HEPATITIS C

Title (fr)
DÉRIVÉS NUCLÉOTIDIQUES QUI SONT DES INHIBITEURS DU VHC POUR UNE UTILISATION DANS LE TRAITEMENT DE L'HÉPATITE C

Publication
EP 3271371 A4 20181205 (EN)

Application
EP 16759215 A 20160302

Priority

- SE 1550242 A 20150302
- SE 1550256 A 20150304
- SE 1550257 A 20150304
- SE 1550258 A 20150304
- SE 1550259 A 20150304
- SE 1550260 A 20150304
- SE 1550261 A 20150304
- SE 1550265 A 20150304
- SE 2016050166 W 20160302

Abstract (en)
[origin: WO2016140615A1] Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovalprevir; or g) grazoprevir and/or elbasvir.

IPC 8 full level
A61K 31/7072 (2006.01); **A61K 31/407** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/439** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/4725** (2006.01); **A61K 31/498** (2006.01); **A61K 31/513** (2006.01); **A61K 38/13** (2006.01); **A61K 38/20** (2006.01); **A61K 38/21** (2006.01); **A61K 38/55** (2006.01); **A61P 31/14** (2006.01); **C07H 19/10** (2006.01)

CPC (source: EP)
A61K 31/407 (2013.01); **A61K 31/4178** (2013.01); **A61K 31/439** (2013.01); **A61K 31/4709** (2013.01); **A61K 31/4725** (2013.01); **A61K 31/498** (2013.01); **A61K 31/513** (2013.01); **A61K 31/7072** (2013.01); **A61K 38/13** (2013.01); **A61K 38/20** (2013.01); **A61K 38/21** (2013.01); **A61K 38/55** (2013.01); **A61K 45/06** (2013.01); **A61P 31/14** (2017.12); **C07H 19/10** (2013.01)

C-Set (source: EP)

1. **A61K 31/7072 + A61K 2300/00**
2. **A61K 38/20 + A61K 2300/00**
3. **A61K 38/55 + A61K 2300/00**
4. **A61K 38/13 + A61K 2300/00**
5. **A61K 31/4709 + A61K 2300/00**
6. **A61K 31/498 + A61K 2300/00**
7. **A61K 31/4725 + A61K 2300/00**
8. **A61K 31/407 + A61K 2300/00**
9. **A61K 31/4178 + A61K 2300/00**
10. **A61K 31/439 + A61K 2300/00**
11. **A61K 31/513 + A61K 2300/00**
12. **A61K 38/21 + A61K 2300/00**

Citation (search report)

- [XDPAY] WO 2015034420 A1 20150312 - MEDIVIR AB [SE]
- [XPAY] WO 2015081297 A1 20150604 - IDENIX PHARMACEUTICALS INC [US]
- See references of WO 2016140615A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2016140615 A1 20160909; CN 107531739 A 20180102; EP 3271371 A1 20180124; EP 3271371 A4 20181205; HK 1243712 A1 20180720

DOCDB simple family (application)
SE 2016050166 W 20160302; CN 201680025360 A 20160302; EP 16759215 A 20160302; HK 18102666 A 20180224